Strategy Driven

MAY 12, 2021

An algorithm processes real-time content for each eye without lag, allowing the 3D world to appear as smooth as in real life, even if you move around. Drug Research —The applications for drug design and biotechnology using 3D displays can be exponential. The content extends deep within the display from any viewing angle.

Technology 100

Technology Content Video Globalization 100

Tanveer Naseer

JUNE 2, 2015

Dan was the president of a biotechnology company where I served in my first middle management role. Unfortunately, as is the case with most great bosses, the time I got to work with Dan was cut short when he accepted an offer for a new leadership position in another organization.

Biotechnology 100

Biotechnology Learning-by-Doing Audience Middle Management 100

Skip Prichard

JULY 22, 2019

You can be the founder of a new process to improve customer service, a more effective way to attract top human capital, a company-sponsored conference or any number of initiatives that bring value to your organization. 6] Being a corporate entrepreneur gets you noticed! But you don’t have to found a new business to get noticed.

Innovation 83

Innovation Social Capital Reputation How To 83

Harvard Business Review

SEPTEMBER 21, 2018

Although directors in certain industries are more aware of the threat of disruption, the widespread lack of board-level engagement in innovation processes could be a major blind spot and a potential liability. These firms also had higher-rated processes for innovation. Setting Priorities. Director Recruitment and Skills.

Innovation 9

Innovation Short-term Telecommunications Long-term 9

Harvard Business Review

FEBRUARY 22, 2017

Using a comprehensive survey, of more than 5,000 directors in over 60 countries, conducted in partnership with WomenCorporateDirectors Foundation , Spencer Stuart, and independent researcher Deborah Bell, we found two main reasons: Boards lack the processes and the expertise they need to surface, evaluate, and address cyberthreats.

Telecommunications 8

Telecommunications Health Care Contingency Plans Biotechnology 8

Harvard Business Review

FEBRUARY 17, 2011

The reason for the interest in in part because the industry has suffered from poor returns on investment over the last decade; indeed, some sectors, including biotechnology, report negative aggregate returns. Investing in a specialty hospital or HMO can accelerate the process of demonstrating value.

Marketing 14

Marketing Venture Capitalist Biotechnology IPO 14

Harvard Business Review

JUNE 23, 2015

So instead of looking at it as a substitute for existing manufacturing, we should look to new areas where it can exploit its unique capabilities to complement traditional manufacturing processes. In these cases, 3D printing has to compete with scale-driven manufacturing processes and rather efficient logistics operations.

Supply Chain 8

Supply Chain Tacit Knowledge Contract Manufacturing Biotechnology 8

Strategy Driven

NOVEMBER 18, 2019

There have also been great leaps forward in biotechnology and even people without investment experience in the industry can find a niche sector to become involved in. From computer hardware and software to technology service providers, app developers and data processing, the potential for growth is seemingly limitless.

Health Care 67

Health Care Biotechnology Energy Insurance 67

Harvard Business Review

SEPTEMBER 11, 2014

For example, a wide variety of clean technologies (including wind, solar, and hydrogen) are vying to power vehicles and cities at the same time that a wide variety of medical technologies (chemical, biotechnological, genomic, and robotic) are being developed to treat diseases. Consider the 2×2 matrix below.

Uncertainty 20

Uncertainty Industry Bottom-up Technology 20

Harvard Business Review

MAY 1, 2014

I learned this while leading a turnaround of NPS Pharmaceuticals , a biotechnology company that now specializes in creating treatments for rare diseases. In the process, I came up with six rules that could also help others change their cultures. To save the 20-year-old company, I had to get it operating like a start-up.

Company 8

Company Pharmaceuticals Biotechnology Short-term 8

Harvard Business Review

DECEMBER 30, 2011

Likewise, they leave too many people behind with an elite selection process that fast-tracks "hi-pos" and essentially discards the rest. That was the question Todd Pierce asked himself in 2006 after years of experimenting with the full menu of trainings, meetings, and competency models in his capacity as CIO of biotechnology giant Genentech.

Development 16

Development Biotechnology CIO Short-term 16

Harvard Business Review

MAY 7, 2018

If you answer yes to any of these questions, then start the process of understanding why you don’t have an invitation. She was on the legal compliance team at a fast-growing biotechnology company. Do you bring knowledge or information that others don’t have? Assess Your Value. Mark was surprised. Elizabeth Grace Saunders.

Restructuring 11

Restructuring How To Compliance Biotechnology 11

Harvard Business Review

MARCH 11, 2014

Isn’t it better to hasten Joseph Schumpeter’s process of creative destruction and move capital and employment from inefficient dinosaurs to more vibrant and agile upstarts? I give them three reasons. First, timing matters. Second, the world of start-ups is narrowly focused.

Innovation 8

Innovation Venture Capitalist Company Supply Chain 8

Harvard Business Review

MAY 28, 2013

Should some specific talent management practices receive greater focus than others--that is, do they exert more influence on competency of an organization''s overall talent management process? pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g., Methodology.

Talent Management 8

Talent Management Company Telecommunications Management 8

Harvard Business Review

MARCH 1, 2012

For example, in biotechnology, a field in which the U.S. Few policy makers realize that much of the innovation that has propelled China's economy, for example, is of the incremental or process type. When it comes to process improvements, American companies are stagnating at best, and in many cases slipping backward. In the U.S.,

Contract Manufacturing 8

Contract Manufacturing Offshoring Supply Chain Biotechnology 8

Harvard Business Review

JULY 16, 2013

Although many boards continue to select new members from their own networks, our research suggests that more are beginning to implement objective processes to select members based on the skills and attributes that boards need to be effective. but also by looking at what skills boards already possess and what skills boards need.

Telecommunications 8

Telecommunications Biotechnology Health Care Real Estate 8

Harvard Business Review

OCTOBER 22, 2013

In order to do this, your company needs a process to source radical ideas that can catapult your business to new heights, open up new markets, or bring in completely unfamiliar profit streams. But in today’s ever-connected world, finding radical ideas seems to be getting tougher for companies. Use Convergence Thinking.

Skills 8

Skills Power Six Sigma Disruptive Innovation 8

Harvard Business Review

MAY 10, 2016

As our research has shown us, the core of the problem is not the high number of M&A deals in itself, but rather that too many executives bring insufficient discipline to the evaluation process that fuels these deals — as a result, they often get deals wrong.

Strategy 8

Strategy Company Biotechnology Franchising 8

Harvard Business Review

JUNE 16, 2016

Innovating the Innovation Process. Simply put, integrating efforts earlier in the process can save enormous amounts of time, money and other resources, while at the same time producing better results. “But here, we can operate within the time frame of the next coffee break.” Putting Manufacturing at the Center.

Technology 8

Technology Venture Capitalist Supply Chain Innovation 8

Harvard Business Review

OCTOBER 23, 2014

Actors in this ecosystem are increasingly working together rather than handing off information or tasks to the next entity in a linear process. That’s why pharmaceutical, biotechnology, and medical device companies need to define their relevance in this new health care ecosystem, and soon. They’re also sharing risk. But not for long.

Health Care 8

Health Care Pharmaceuticals Information Technology Supply Chain 8

Harvard Business Review

MARCH 5, 2012

Indian companies, for instance, are already doing quite well exporting services like software development, technical support, and back-office processing to America. This tight connection between R&D, innovation, and production is present in sectors like biotechnology, advanced materials, and nanotechnology. The Right Policies.

Health Care 8

Health Care Biotechnology Industry Policies 8

Harvard Business Review

JUNE 12, 2012

trillion in government support for seven "strategic emerging industries," including alternative energy, biotechnology, next-gen IT, high-end manufacturing equipment, and advanced materials. A decade from now we may look back at China's 12th Five-Year Plan as the seminal document of the early 21st century. It pledges $1.5

First-mover Advantage 8

First-mover Advantage GDP Technology Biotechnology 8

Harvard Business Review

SEPTEMBER 14, 2011

Chirotech specializes in biocatalysis and chemocatalysis, two important subspecialties of biotechnology and chemistry that help develop key biological and chemical intermediates needed for the efficient production of medicines.

Globalization 9

Globalization Innovation Decentralization Chemicals 9

Harvard Business Review

MAY 15, 2015

Works like these are reflections of the American story, which has always experienced tension between its narrative of meritocratic social mobility, its long history of racial inequality, and the boom-bust economic cycles that have allowed rapacious monopolists to manipulate the political process with impunity.

Class 8

Class Open-book Politics Biotechnology 8

Harvard Business Review

FEBRUARY 3, 2015

As these managers start to concern themselves with broad strategic issues and organizational change processes, lateral relationships with people outside their immediate area become even more critical to the manag­ers’ ability to get things done.

How To 8

How To Diversity Letter Learning-by-Doing 8

Harvard Business Review

NOVEMBER 29, 2016

But in the past, EHR data was often limited to a single research institution or provider network, and obtaining the data needed to help answer a specific research question usually involved a tedious and inefficient process.

Pharmaceuticals 8

Pharmaceuticals Incubator Health Care Biotechnology 8

Harvard Business Review

APRIL 19, 2016

In virtually every advanced field, whether it’s information technology, biotechnology, agriculture, or renewable energy, America holds a leading position. As Bush wrote in 1945: “New products and new processes do not appear full-grown. In the pharmaceutical industry, the monitoring process can be incredibly elaborate.

Innovation 8

Innovation Company Competitive Advantage Venture Funding 8

Harvard Business Review

MARCH 30, 2017

Cognitive diversity has been defined as differences in perspective or information processing styles. It measures: Knowledge processing: the extent to which individuals prefer to consolidate and deploy existing knowledge, or prefer to generate new knowledge, when facing new situations. We worked with a startup biotechnology company.

Diversity 8

Diversity Team Biotechnology Execution 8

Harvard Business Review

NOVEMBER 9, 2016

Intense biotechnology research and development activities at some of the country’s universities (and their research farms) have raised the complexity and level of the industry’s outputs. New processing methods have resulted in organic dairy ingredients and even infant formula made from goat milk.

Cooper 12

Cooper Long-term Industry Health Care 12

Harvard Business Review

AUGUST 23, 2016

” Directors of both political views rate their boards similarly on processes, dynamics, and effectiveness as a whole, but differ on the question of compensation. pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g.,

Politics 8

Politics Committee Telecommunications Diversity 8